Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · IEX Real-Time Price · USD
7.85
+0.10 (1.29%)
At close: Jul 19, 2024, 4:00 PM
7.79
-0.06 (-0.83%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Ocular Therapeutix Revenue
Ocular Therapeutix had revenue of $59.84M in the twelve months ending March 31, 2024, with 15.79% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $14.77M with 10.47% year-over-year growth. In the year 2023, Ocular Therapeutix had annual revenue of $58.44M with 13.49% growth.
Revenue (ttm)
$59.84M
Revenue Growth
+15.79%
P/S Ratio
20.32
Revenue / Employee
$224,127
Employees
267
Market Cap
1.22B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
Dec 31, 2019 | 4.23M | 2.24M | 112.41% |
Dec 31, 2018 | 1.99M | 67.00K | 3.48% |
Dec 31, 2017 | 1.92M | 36.00K | 1.91% |
Dec 31, 2016 | 1.89M | 137.00K | 7.83% |
Dec 31, 2015 | 1.75M | 978.00K | 126.68% |
Dec 31, 2014 | 772.00K | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 10.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Omnicell | 1.10B |
AtriCure | 414.60M |
Artivion | 368.21M |
Maravai LifeSciences Holdings | 274.10M |
Xencor | 162.18M |
Ardelyx | 159.11M |
Establishment Labs Holdings | 155.79M |
Prothena Corporation | 89.25M |
OCUL News
- 3 days ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting - GlobeNewsWire
- 13 days ago - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
- 5 weeks ago - Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study - GlobeNewsWire
- 6 weeks ago - Ocular Therapeutix® to Host Investor Day on June 13, 2024 - GlobeNewsWire
- 6 weeks ago - Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Ocular Therapeutix™ Reports First Quarter 2024 Results - GlobeNewsWire